All In Biotech

Drug Trial Radar · NCT05461170

SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.

A Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of VIR-2218 and VIR-3434 in Participants With Chronic Hepatitis D Virus Infection (SOLSTICE)

Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

95

Actual

Start

Sep 17, 2022

Primary completion

Nov 2031

Study completion May 2032

Sponsor

Lead sponsor
Vir Biotechnology, Inc.Industry
Sponsor type
Industry
First posted
Jul 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 69 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2 trial in which participants with chronic hepatitis D virus (HDV) infection will receive VIR-2218 and/or VIR-3434 and be assessed for safety, tolerability, and efficacy

Conditions

  • Hepatitis D, Chronic

Interventions

  • VIR-2218Drug

    VIR-2218 given by subcutaneous injection

  • VIR-3434Drug

    VIR-3434 given by subcutaneous injection

  • NRTIDrug

    NRTI given orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with undetectable HDV RNA (< limit of detection [LOD]) or ≥ 2 log10 decrease in HDV RNA from baseline and alanine aminotransferase (ALT) normalization (ALT < upper limit of normal [ULN]) at Week 24Time frame: Up to 24 Weeks
  2. Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: Up to 360 Weeks

Locations

20 sites in 9 countries. Site status is shown where the registry gives one.

  • Investigative Site

    Sofia, Bulgaria

  • Investigative Site

    Sofia, Bulgaria

  • Investigative Site

    Stara Zagora, Bulgaria

  • Investigative Site

    Clichy, France

  • Investigative Site

    Pessac, France

  • Investigative Site

    Rennes, France

  • Investigative Site

    Toulouse, France

  • Investigative Site

    Frankfurt, Germany

  • Investigative Site

    Hanover, Germany

  • Investigative Site

    Tübingen, Germany

  • Investigative Site

    Milan, Italy

  • Investigative Site

    Pisa, Italy

  • Investigative Site

    Chisinau, Moldova

  • Investigative Site

    Rotterdam, Netherlands

  • Investigative Site

    Auckland, New Zealand

  • Investigative Site

    Bucharest, Romania

  • Investigative Site

    Birmingham, United Kingdom

  • Investigative Site

    London, United Kingdom

  • Investigative Site

    London, United Kingdom

  • Investigative Site

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.